Pharmaceutical API domestic marketing

Pharmaceutical API domestic marketing

    Nanjing Pharmacare has established long-term strategic partnerships with a number of internationally renowned pharmaceutical leading companies, and its agents cover multiple therapeutic areas such as cardiovascular, central nervous system, anti-tumor, and respiratory systems.

    Pharmacare focuses on studying the dynamics of the Chinese pharmaceutical market and discovering the needs of customers. Committed to providing domestic customers with imported APIs of good quality, new varieties and scarce markets, helping domestic customers to obtain the first generic drugs license, seizing the market, and improving competitiveness, and the APIs we provide will be registered in the United States and Europe at the same time. It is beneficial for domestic partners to register formulation products in the United States and Europe.
At present, Pharmacare has established cooperation with more than ten well-known domestic listed pharmaceutical companies, and its business has grown and grown year by year, and the services provided have been highly praised and recognized by the industry.

Our suppliers:
Having strict quality control system, complete documentation system ,regulatory registration experience covering the global mainstream pharmaceutical regulatory, and excellent customer service awareness, so as to ensure that they can provide stable and reliable services to global formulation customers; They are also long-term partners with inventors.
Our products:
Sufficient price advantage, supporting customers to control the cost of APIs in the R&D and commercial production stages, and fully guaranteeing the competitiveness of the current domestic pharmaceutical policies and the commercial environment
Reliable quality and sufficient impurity research provide strong guarantee for customers to conduct consistency evaluation
Complete DMF data to meet various requirements of customers
Supported by the global supply chain, it generally has production capacity advantages and guarantees stable supply, which can not only ensure the progress of customer research and development, but also provide supply guarantee for customers to participate in domestic procurement
Our team:
Understand the products, we have professionals who have been engaged in drug research and development for more than ten years, and we can conduct efficient and professional technical docking with the R&D project team
Understand the laws and regulations, we have a professional regulatory registration team with rich experience in domestic registration.
Understand the market, we have extensive and in-depth cooperation with well-known domestic pharmaceutical companies, and fully understand the current domestic pharmaceutical market macro environment and the actual needs of customers. Thinking from the customer’s needs is the basic point of our company’s API sales strategy. To provide customers with The API with the greatest commercial value is our goal.
Pharmacare has always kept up with the development trend of the pharmaceutical market. In order to provide customers with more comprehensive services, Pharmacare will also strive to expand its formulation import business.
"Integrity, professionalism, efficiency, pragmatism, innovation, and self-discipline" are the business philosophy that Pharmacare has always upheld. For many years, Pharmacare has been committed to providing customers with high-quality services, creating value, and achieving win-win cooperation in the industry. A good reputation. Pharmacare people will continue to work hard to create a better future hand in hand with customers.

    Mrs.Lisa, +86-25-86622972, lisa@fmkpharm.com

    Mr.Jerry, +86-25-86622645, jerry.yao@fmkpharm.com

Download all product descriptions

NO. Product Name USDMF NMPA Whether can support to formulation technical transfer Indications
1 Dabigatran Etexilate Mesylate Y FDA:27037 A EU:√ CDE: Y20190000613 I Y Cardiovascular
2 Carboprost Trometamol Y Y20200000103 Drainage contraction
3 Lurasidone Hydrochloride Y Y20190000477、2020 planning Y Antipsychotic
4 Vildagliptin Diabetes
5 Rosuvastatin Calcium Y Y20190000940 Y Anti-hyperlipidemia
6 Empagliflozin  Y 2020 planning Diabetes
7 Avanafil  Y 2020 planning pulmonary hypertension
8 Linagliptin Y 2020 planning Y Diabetes
9 Posaconazole Y 2020 planning Antifungal
10 Rivaroxaban Y 2020 planning Y Cardiovascular
11 Duloxetine Hydrochloride Y 2020 planning Antidepressant
12 Aripiprazole  Y 2020 planning Anti-epileptic
13 Eslicarbazepine Acetate Y Anti-epileptic
14 Pioglitazone Hydrochloride Y Y20170001510、Y20190021512 Diabetes